Showing results (41-50 of 100) with videos related to

Sort By:
Pageof 10
Hematological Oncology|August 6, 2024
Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors-The MicroLinf StudyBeatrice Casadei, Gabriele Conti, Monica Barone, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 24, 2011
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trialPier Luigi Zinzani, Cinzia Pellegrini, Letizia Gandolfi, et al.
Cancer|October 21, 2010
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphomaPier Luigi Zinzani, Letizia Gandolfi, Alessandro Broccoli, et al.
The Oncologist|May 30, 2014
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphomaCinzia Pellegrini, Lisa Argnani, Alessandro Broccoli, et al.
Hematological Oncology|September 27, 2014
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patientsPier Luigi Zinzani, Alessandro Broccoli, Beatrice Casadei, et al.
BMC Cancer|April 19, 2017
The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patientsAlessandro Broccoli, Beatrice Casadei, Vittorio Stefoni, et al.
BMC Cancer|November 11, 2015
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experienceEnrico Derenzini, Vittorio Stefoni, Cinzia Pellegrini, et al.
Cancer|July 3, 2010
Hairy cell leukemia: evaluation of the long-term outcome in 121 patientsPier Luigi Zinzani, Cinzia Pellegrini, Vittorio Stefoni, et al.
Journal of Hematology & Oncology|April 14, 2016
A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patientsCinzia Pellegrini, Anna Dodero, Annalisa Chiappella, et al.
British Journal of Haematology|February 26, 2026
Immune-related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitorsLisa Argnani, Vittorio Stefoni, Beatrice Casadei, et al.
Pageof 10